EA202090004A1 - Биспецифические антитела против pd-1 и против tim-3 - Google Patents
Биспецифические антитела против pd-1 и против tim-3Info
- Publication number
- EA202090004A1 EA202090004A1 EA202090004A EA202090004A EA202090004A1 EA 202090004 A1 EA202090004 A1 EA 202090004A1 EA 202090004 A EA202090004 A EA 202090004A EA 202090004 A EA202090004 A EA 202090004A EA 202090004 A1 EA202090004 A1 EA 202090004A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- tim
- cell
- bind
- variable domain
- bspecific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
В документе предложены средства и способы препятствования, опосредуемому белком, запрограммированной гибели клеток 1 (PD-1) и белком 3 Т-клеток, содержащим домен иммуноглобулина и домен муцина (TIM-3), ингибированию в PD-1-положительной и/или TIM-3-положительной клетке. Способ может включать приведение указанной клетки в контакт с антителом или его функциональной частью, производным и/или аналогом, содержащими вариабельный домен, который может связываться с внеклеточной частью PD-1, и вариабельный домен, который может связываться с внеклеточной частью TIM-3, тем самым ингибируя опосредуемую PD-1 и/или TIM-3 активность в указанной клетке. В документе также предложены антитела или их варианты, содержащие вариабельный домен, который может связываться с внеклеточной частью PD-1, и вариабельный домен, который может связываться с внеклеточной частью TIM-3.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17180061 | 2017-07-06 | ||
PCT/NL2018/050450 WO2019009727A1 (en) | 2017-07-06 | 2018-07-06 | ANTI-PD1 ANTI-TIM3 BISPECIFIC ANTIBODIES |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202090004A1 true EA202090004A1 (ru) | 2020-06-18 |
Family
ID=59366222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202090004A EA202090004A1 (ru) | 2017-07-06 | 2018-07-06 | Биспецифические антитела против pd-1 и против tim-3 |
Country Status (15)
Country | Link |
---|---|
US (2) | US11753470B2 (ru) |
EP (1) | EP3649155A1 (ru) |
JP (1) | JP7422655B2 (ru) |
KR (1) | KR20200042467A (ru) |
CN (1) | CN111094348A (ru) |
AU (1) | AU2018297058B2 (ru) |
BR (1) | BR112020000227A2 (ru) |
CA (1) | CA3068932A1 (ru) |
EA (1) | EA202090004A1 (ru) |
IL (1) | IL271832A (ru) |
MX (1) | MX2020000055A (ru) |
PH (1) | PH12020550013A1 (ru) |
SG (1) | SG11202000054RA (ru) |
TW (1) | TW201920657A (ru) |
WO (1) | WO2019009727A1 (ru) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3649156A1 (en) * | 2017-07-06 | 2020-05-13 | Merus N.V. | Antibodies that modulate a biological activity expressed by a cell |
TWI804572B (zh) * | 2018-02-09 | 2023-06-11 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
MX2020010267A (es) * | 2018-03-30 | 2020-11-06 | Merus Nv | Anticuerpo multivalente. |
EP3966247A4 (en) * | 2019-05-06 | 2023-01-04 | Brown University | B-SPECIFIC ANTIBODIES AGAINST CHI3L1 AND PD1 WITH ENHANCED T-LYMPHOCYTE-MEDIATED CYTOTOXIC EFFECTS ON TUMOR CELLS |
SG11202112399PA (en) | 2019-05-09 | 2021-12-30 | Merus Nv | Variant domains for multimerizing proteins and separation thereof |
CN113563473A (zh) * | 2020-04-29 | 2021-10-29 | 三生国健药业(上海)股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
AR127714A1 (es) * | 2021-11-19 | 2024-02-21 | Merus Nv | UNIDADES DE UNIÓN MULTIESPECÍFICAS QUE COMPRENDEN LOS DOMINIOS DE UNIÓN A PD-1 Y TGF-bRII |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
JP4836451B2 (ja) | 2002-07-18 | 2011-12-14 | メルス ベー ヴェー | 抗体混合物の組換え生産 |
CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
JP5639039B2 (ja) | 2008-04-11 | 2014-12-10 | メリマック ファーマシューティカルズ インコーポレーティッド | ヒト血清アルブミンリンカーおよびそのコンジュゲート |
EP3456190B1 (en) | 2008-06-27 | 2021-11-24 | Merus N.V. | Antibody producing transgenic murine animal |
WO2011159877A2 (en) * | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
PT2838917T (pt) | 2012-04-20 | 2019-09-12 | Merus Nv | Métodos e meios para a produção de moléculas similares a ig heterodiméricas |
DK2900694T3 (en) | 2012-09-27 | 2018-11-19 | Merus Nv | BISPECIFIC IGG ANTIBODIES AS T-CELL ACTIVATORS |
WO2015130173A1 (en) * | 2014-02-28 | 2015-09-03 | Merus B.V. | Antibody that binds erbb-2 and erbb-3 |
EP3356821B1 (en) * | 2015-10-02 | 2019-10-23 | H. Hoffnabb-La Roche Ag | Cellular based fret assay for the determination of simultaneous binding |
EP3356411B1 (en) * | 2015-10-02 | 2021-06-30 | F. Hoffmann-La Roche AG | Bispecific antibodies specific for pd1 and tim3 |
KR20180100305A (ko) * | 2015-10-23 | 2018-09-10 | 메뤼스 엔.페. | 암 성장을 억제하는 결합 분자 |
AU2016348391A1 (en) * | 2015-11-03 | 2018-05-17 | Janssen Biotech, Inc. | Antibodies specifically binding TIM-3 and their uses |
-
2018
- 2018-07-06 MX MX2020000055A patent/MX2020000055A/es unknown
- 2018-07-06 AU AU2018297058A patent/AU2018297058B2/en active Active
- 2018-07-06 US US16/628,937 patent/US11753470B2/en active Active
- 2018-07-06 WO PCT/NL2018/050450 patent/WO2019009727A1/en unknown
- 2018-07-06 TW TW107123602A patent/TW201920657A/zh unknown
- 2018-07-06 JP JP2020500087A patent/JP7422655B2/ja active Active
- 2018-07-06 EP EP18749180.8A patent/EP3649155A1/en active Pending
- 2018-07-06 CA CA3068932A patent/CA3068932A1/en active Pending
- 2018-07-06 EA EA202090004A patent/EA202090004A1/ru unknown
- 2018-07-06 KR KR1020207003656A patent/KR20200042467A/ko not_active Application Discontinuation
- 2018-07-06 BR BR112020000227-5A patent/BR112020000227A2/pt unknown
- 2018-07-06 SG SG11202000054RA patent/SG11202000054RA/en unknown
- 2018-07-06 CN CN201880055838.7A patent/CN111094348A/zh active Pending
-
2020
- 2020-01-05 IL IL271832A patent/IL271832A/en unknown
- 2020-01-06 PH PH12020550013A patent/PH12020550013A1/en unknown
-
2023
- 2023-07-26 US US18/359,660 patent/US20230357407A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20200042467A (ko) | 2020-04-23 |
MX2020000055A (es) | 2020-08-06 |
US20200216539A1 (en) | 2020-07-09 |
JP7422655B2 (ja) | 2024-01-26 |
BR112020000227A2 (pt) | 2020-09-29 |
CN111094348A (zh) | 2020-05-01 |
US20230357407A1 (en) | 2023-11-09 |
AU2018297058B2 (en) | 2021-04-29 |
JP2020532281A (ja) | 2020-11-12 |
SG11202000054RA (en) | 2020-02-27 |
IL271832A (en) | 2020-02-27 |
CA3068932A1 (en) | 2019-01-10 |
WO2019009727A1 (en) | 2019-01-10 |
TW201920657A (zh) | 2019-06-01 |
EP3649155A1 (en) | 2020-05-13 |
AU2018297058A1 (en) | 2020-01-30 |
WO2019009727A8 (en) | 2020-01-30 |
US11753470B2 (en) | 2023-09-12 |
PH12020550013A1 (en) | 2020-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202090004A1 (ru) | Биспецифические антитела против pd-1 и против tim-3 | |
EA202090005A1 (ru) | Антитела, модулирующие биологическую активность, проявляемую клеткой | |
SA518390862B1 (ar) | Pd-l1 أجسام مضادة ضد | |
SA518390903B1 (ar) | أجسام مضادة لـ جديدة pd-1 | |
EA201991156A1 (ru) | АНТИТЕЛА К Tim-3 ДЛЯ КОМБИНАЦИИ С АНТИТЕЛАМИ К PD-1 | |
BR112019008494A2 (pt) | anticorpos para pd-1 e usos dos mesmos | |
MY201526A (en) | Anti-trem2 antibodies and methods of use thereof | |
PH12017502222A1 (en) | Lag-3-binding molecules and methods of use thereof | |
MA46113A (fr) | Anticorps dirigés contre l'immunoglobuline de lymphocyte t et la protéine 3 de mucine (tim-3) | |
MY191649A (en) | Antibodies to tigit | |
PH12020551930A1 (en) | Anti-sirpa antibodies and methods of use thereof | |
MX2019013033A (es) | Formulaciones estables de anticuerpos anti-tigit solos y en combinacion con anticuerpos anti-receptor de muerte programada 1 (pd-1) y metodos para su uso. | |
EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
TN2019000294A1 (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
BR112016014022A2 (pt) | anticorpos anti-cd3, ácido nucleico isolado, vetor, célula hospedeira, método de produção do anticorpo anti-cd3, imunoconjugado, composição, uso do anticorpo anti-cd3, métodos de tratamento, métodos de intensificação da função imune e kit | |
WO2017075432A3 (en) | Anti-siglec-9 antibodies and methods of use thereof | |
NZ734256A (en) | Use of plinabulin in combination with immune checkpoint inhibitors | |
EA201990747A1 (ru) | Способы лечения иммунных нарушений с применением белков, связывающих pd–1 | |
EA202090746A1 (ru) | Двойные ингибиторы путей tim-3 и pd-1 | |
EA202190138A1 (ru) | Анти-sirp-бета1 антитела и способы их использования | |
MX2018012939A (es) | Moleculas de union especificas para receptor fc gamma humano iia y usos de las mismas. | |
PH12021550332A1 (en) | Anti-cd33 antibodies and methods of use thereof | |
MX2016011177A (es) | Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos. | |
EA201992186A1 (ru) | Антитела к par2 и пути их применения | |
AR109262A1 (es) | Anticuerpos contra tim3 y sus usos |